Similar articles

• [Relationship between malignant hyperthermia and myopathy].

  Schellnack K, Regling G, Hofmann J, Buntrock P, Martin H, Hecht H. Schellnack K, et al. Neurologija. 1977;25 Spec No:109-12. Neurologija. 1977. PMID: 757254 Croatian. No abstract available.
• [King's syndrome. Malignant hyperthermia].

  Artigas i Pallarés J, Argemi i Renom J, Miró i Bedós X, Sancho i Oliver S, Navarró Fernandez-Balbuena C, Lechuga Campoy JL. Artigas i Pallarés J, et al. An Esp Pediatr. 1990 Jul;33(1):66-8. An Esp Pediatr. 1990. PMID: 2252292 Spanish. No abstract available.
• Malignant hyperthermia associated with myopathy and normal muscle enzymes.

  Kaplan AM, Bergeson PS, Gregg SA, Curless RG. Kaplan AM, et al. J Pediatr. 1977 Sep;91(3):431-4. doi: 10.1016/s0022-3476(77)81314-0. J Pediatr. 1977. PMID: 894412 No abstract available.
• Core myopathies and risk of malignant hyperthermia.

  Klingler W, Rueffert H, Lehmann-Horn F, Girard T, Hopkins PM. Klingler W, et al. Anesth Analg. 2009 Oct;109(4):1167-73. doi: 10.1213/ANE.0b013e3181b5ae2d. Anesth Analg. 2009. PMID: 19762745 Review.
• Can inhalation agents be used in the presence of a child with myopathy?

  Veyckemans F. Veyckemans F. Curr Opin Anaesthesiol. 2010 Jun;23(3):348-55. doi: 10.1097/ACO.0b013e3283393977. Curr Opin Anaesthesiol. 2010. PMID: 20421788 Review.